Julphar announces full year 2015 financial results: 6% sales growth with net profit of AED 226 million
Following its Board of Directors’ meeting at its Ras Al Khaimah head office – Julphar Gulf Pharmaceutical Industries, the largest generic pharmaceutical manufacturer in Middle East and North Africa (MENA), announced it has closed the year 2015 at AED 1.47 billion, with a growth of 6 per cent against 2014 sales of 1.39 billion.
The company demonstrated a steady operational performance during 2015, posting 11.1 per cent year-on-year rise in its gross profits for the year ending 2015, which was AED 908.9 million. Julphar’s net profit for the period was AED 226.6 million, up 12.2 per cent year-on-year.
“2015 has been another year of great achievements for Julphar and we are excited to head into another stimulating year,” said Dr Ayman Sahli, Chief Executive Officer of Julphar. “As one of the UAE’s most ambitious local businesses, we strive to make an impact in the global industry and thrive in international markets. With manufacturing facilities in Ethiopia and Bangladesh, we have plan to expand our global manufacturing presence with the launch of our third international plant in KSA, which is expected to begin its operations during 2016.”
“Closing the year 2015 at AED 1.47 billion shows a remarkable effort from Julphar’s employees and sales team, and highlights true dedication from our staff all around the world,” he added. “We will keep on working hard to deliver our mission to provide high quality, affordable medicines to communities, as this is – and will remain – at the core of our business strategy.”